Assessing Donor and Platelet Transfusion Characteristics on Intracranial Hemorrhage Outcomes

• Published in: Blood 2023-11, Vol.142 (Supplement 1), p.4038-4038
• Main Authors: Roh, David, Davis, Jonathan M, Lee, Travis, Mitchell, Patrick M, Bookwalter, Deborah, Stone, Elizabeth, Karafin, Matthew S., Cushing, Melissa M., Spencer, Bryan R, Bruhn, Roberta, Gottschall, Jerome L., Mast, Alan E., Cable, Ritchard G., Kleinman, Steven, Hod, Eldad A.
• Format: Article
• Language: English
• ISSN: 0006-4971; 1528-0020
• DOI: 10.1182/blood-2023-180236

Introduction: Intracranial hemorrhage (ICH) patients require rapid treatment to reverse coagulopathy, which can help establish hemorrhage control and improve outcomes. While acute platelet transfusions are given in ICH to reverse platelet dysfunction, delays in administration of hemorrhage control therapies and platelet unit characteristics themselves may impact the efficacy and clinical outcomes in different patient populations. Thus, we sought to evaluate the relationship of platelet transfusion timing and platelet unit characteristics with ICH mortality. Methods: Available data for incident hospitalizations of adult ICH patients between 2019-2022 from 3 of the 5 participating sites within the multicenter REDS-IV-P network were assessed. ICH patients were included if they received ≥ 1 acute platelet transfusion within 48 hours of admission and presented with one of the following ICH etiologies: trauma (tICH), spontaneous intracerebral hemorrhage (sICH), and aneurysmal subarachnoid hemorrhage (aSAH). Patients with early withdrawal of care and death within the first 48 hours were excluded. Separate logistic regression models (each adjusting for age, sex, race/ethnicity, comorbidities, and number of platelet transfusions) assessed the relationship of 30 day ICH mortality outcome with the following: a) time to initial platelet transfusion in hour quartiles: